Feed VNRX
VN

VolitionRx Limited

VNRX · AMEX

$0.26 +0.04% (+$0.00)
1M -33.50%
Market Cap $3.14M
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$0.33

26.9% upside

Trenutna cena

$0.26

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica VNRX trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
98 /100
Cheap
P/S 1.28x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing
Rev. growth 77.98%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak
Gross margin 89.65%
Net margin 1,043.11%
Op. margin 786.69%
Quality
62 /100
Average
ROIC 5,674.42%
ROA 308.88%
Asset turnover 0.30x
Debt
0 /100
High
Current ratio 0.30x
Int. coverage -5.41x
Debt/Equity N/A
Stability
50 /100
Moderate
Beta 1.10x
Rev. volatility 60.50%
EPS volatility 14.80%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o VNRX
Online

O podjetju

VolitionRx Limited is a biotechnology company based in Belgium that focuses on the development and commercialization of tests based on epigenetic biomarkers for the diagnosis of various types of cancer and other diseases. Their main product is a test called Nu.QTM, which utilizes nucleosomal biomarker detection technology to determine the presence of cancer in the body. This test is designed to be non-invasive, reliable, and sensitive to various types of cancer, allowing for quick and accurate diagnosis. VolitionRx Limited aims to provide innovative diagnostic tools that can improve the detection of cancer and other diseases in early stages and contribute to better treatment and prognosis for patients.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Devices

CEO

Cameron Reynolds

Employees

57

Headquarters

Henderson

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

52d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.